Showing 81 - 100 results of 18,137 for search 'significantly ((((larger decrease) OR (((we decrease) OR (a decrease))))) OR (greatest decrease))', query time: 0.39s Refine Results
  1. 81
  2. 82
  3. 83
  4. 84

    Flow chart of sediment P fractionation procedure. by Jiayu Hu (673291)

    Published 2025
    “…The NH<sub>4</sub>Cl-Po and NaHCO<sub>3</sub>-Po concentrations in sediments showed the greatest decrease (accounting for 97.6% of total decrease) during the experiment. …”
  5. 85
  6. 86
  7. 87
  8. 88
  9. 89
  10. 90

    Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b> by Chang Seok Han (21814121)

    Published 2025
    “…In addition, genetic variation in age-related plasticity in exploration contributed to a decrease in the magnitude of genetic correlations during the adult stage. …”
  11. 91
  12. 92

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  13. 93

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  14. 94

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  15. 95
  16. 96
  17. 97
  18. 98
  19. 99

    Scheme of g-λ model with larger values λ. by Zhanfeng Fan (20390992)

    Published 2024
    “…The findings suggest that when λ is respectively equal to 4.19, 8.57, 10, and 12.15, the peak particle velocity (PPV) of the transmitted waves is significantly close to the incident wave amplitude. Furthermore, when λ is fixed, the energy transmission coefficient increases with the incident wave amplitude but decreases with the incident wave frequency. …”
  20. 100